)

Adverum Biotechnologies (ADVM) investor relations material
Adverum Biotechnologies H.C. Wainwright 5th Annual Ophthalmology Virtual Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Key clinical developments
Advancing a gene therapy for wet AMD, currently in phase three with Ixavec, which delivers sustained aflibercept to the retina.
Phase one OPTIC and phase two LUNA trials showed up to 50% injection freedom and 80% reduction in treatment burden for hard-to-treat patients.
Four-year OPTIC data demonstrated maintained vision and significant reduction in retinal fluid, with nearly half of patients remaining injection free.
LUNA trial confirmed high injection-free rates and dramatic treatment burden reduction, especially in patients with lower prior injection frequency.
Safety profile improved with lower doses and enhanced steroid prophylaxis, with minimal inflammation and high patient preference for the therapy.
Market opportunity and unmet need
Wet AMD affects over 1.5 million in the US and 20 million globally, with a growing patient pool due to aging populations.
Despite anti-VEGF therapies, under-treatment remains common, leading to vision decline; durability is the leading unmet need.
Gene therapy is viewed as the most promising modality for extended treatment duration by retina specialists.
Ixavec offers the highest injection-free rates among ocular gene therapies, with a significant advantage over competitors.
Wet AMD could become the first mass market gene therapy indication, with potential for broad adoption and mass market pricing.
Forward-looking statements and next steps
ARTEMIS phase three trial is enrolling ahead of schedule, targeting a broad patient population and aiming for non-inferiority in vision outcomes.
Second phase three trial, Aquarius, is planned to start in the second half of the year.
Additional two-year follow-up data from LUNA expected in Q4 this year.
Anticipates seamless integration into retina practices due to the established use of aflibercept.
Long-term vision is to expand gene therapy adoption from high-need patients to all wet AMD patients.
Next Adverum Biotechnologies earnings date

Next Adverum Biotechnologies earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage